News round-up for 11-15 September by DDW Digital Content Editor Diana Spencer.
Spanning artificial intelligence, theranostics, radiopharmaceuticals, quantum simulation and small regulatory RNA, the top stories this week all cover cutting-edge technologies and techniques making a huge impact on modern drug discovery and development.
Artificial intelligence (AI) technology has the potential to revolutionise drug discovery and pharma companies need to make plans for a future in which AI is frequently utilised in research, says ResearchAndMarkets.com.
Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has dosed the first patient with its first-in-class lead molecule, satoreotide, targeting extensive stage small cell lung cancer (ES-SCLC).
Kuano, a drug discovery company combining quantum mechanics with AI to design the next generation of medicines, has raised £1.8M in seed funding, which will facilitate further validation of Kuano’s quantum simulation platform for the design of more effective drug candidates targeting enzymes.
Orano Med, a biotechnology company developing Lead-212 (212Pb) targeted alpha therapy against cancer, and Orbit Discovery, a company discovering therapeutic peptide hits, have entered into a collaboration to discover specific peptide receptor radionuclide therapies (PRRT) against cancer cells and advance the development of novel radiopharmaceuticals.
Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies. The trial, which marks the first time a human has been dosed with Replicate’s srRNA technology, will serve as a benchmark for utility in this indication and other complex infectious diseases.